Vanda Pharmaceuticals | VNDA - Debt


Vanda Pharmaceuticals reported $4.96M in Debt for its fiscal quarter ending in December of 2024.





Debt Change Date
Acadia Pharmaceuticals USD 54.81M 1.48M Sep/2025
Agios Pharmaceuticals USD 44.52M 4.24M Sep/2025
Akebia Therapeutics USD 46.51M 7.82M Mar/2025
Alnylam Pharmaceuticals USD 1.31B 11.39M Sep/2025
Anika Therapeutics USD 0 0 Mar/2025
Arrowhead Research USD 366.28M 13.25M Sep/2025
AstraZeneca USD 32.63B 207M Sep/2025
Bristol-Myers Squibb USD 51.04B 112M Sep/2025
Eli Lilly USD 42.51B 2.6B Sep/2025
Enanta Pharmaceuticals USD 1.35M 0 Dec/2024
Esperion Therapeutics USD 262.92M 1.76M Sep/2024
Halozyme Therapeutics USD 1.51B 1.66M Sep/2025
Heron Therapeutics USD 149.65M 157K Sep/2024
Insmed USD 727.89M 163.33M Dec/2025
J&J USD 45.8B 4.97B Sep/2025
Lexicon Pharmaceuticals USD 99.26M 493K Sep/2023
Ligand Pharmaceuticals USD 451M 445.26M Sep/2025
Merck USD 41.37B 5.97B Sep/2025
Minerva Neurosciences USD 0 0 Sep/2024
Moderna USD 734M 7M Sep/2025
Novartis USD 32.02B 615M Sep/2025
Pfizer USD 60.85B 78M Sep/2025
PTC Therapeutics USD 286.32M 306K Sep/2025
Puma Biotechnology USD 89.06M 55.07M Jun/2024
Sangamo BioSciences USD 0 0 Jun/2022
Sanofi EUR 21.76B 530M Sep/2025
Takeda JPY 4.85T 208B Dec/2025
Teva Pharmaceutical Industries USD 17.07B 450M Sep/2025
Ultragenyx Pharmaceutical USD 33.83M 2.46M Sep/2025
Vanda Pharmaceuticals USD 4.96M 4.96M Dec/2024
Veracyte USD 40.45M 10.19M Sep/2025